Results 1 to 10 of about 694 (96)

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database [PDF]

Frontiers in Pharmacology
BackgroundRipretinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GISTs) who have previously received treatment with at least three kinase inhibitors.
Ye Hu, Linlin Zhang, Qineng Gong, Lei Huang, Cunlin Yin, Yang Miao, Hui Wu   +6 more
exaly   +4 more sources

Case Report: Neoadjuvant therapy with ripretinib for gastrointestinal stromal tumor: a case report [PDF]

Frontiers in Pharmacology
Neoadjuvant therapy targeting genotype-specific gastrointestinal stromal tumors (GISTs) may be indicated in select cases. While the majority of patients respond to Imatinib with a reduction in tumor size, some exhibit either poor response or resistance ...
Chenggang Zhang, Weiming Kang, Kang Weiming   +2 more
exaly   +4 more sources

A real-world disproportionality analysis of ripretinib data mining of the public version of FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundTyrosine kinase inhibitors (TKIs) are the preferred targeted therapy for advanced gastrointestinal stromal tumors (GIST). Ripretinib, the first tyrosine kinase switch control inhibitor, has not yet been extensively studied for long-term safety ...
Yingkai Feng, Xinyu Fa, Yifei Wang, Tao Zhang, Xuan Sun, Faping Li   +5 more
exaly   +4 more sources

USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition [PDF]

Advanced Science
Ripretinib, a broad‐spectrum inhibitor of the KIT and PDGFRA receptor tyrosine kinases, is designated as a fourth‐line treatment for gastrointestinal stromal tumor (GIST). It is tailored for patients resistant to imatinib, sunitinib, and regorafenib.
Hao Xu
exaly   +3 more sources

Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS) [PDF]

Frontiers in Pharmacology
ObjectiveThis study aims to analyze potential adverse events (AEs) associated with ripretinib and sunitinb in gastrointestinal stromal tumor (GIST) treatment using data from the FDA Adverse Event Reporting System (FAERS).
Xinzhen Che, Yong Zhu
doaj   +2 more sources

Liquid chromatography-tandem mass spectrometry for the quantification of ripretinib and its metabolites DP-5439 in human plasma [PDF]

Frontiers in Pharmacology
BackgroundRipretinib, a broad-spectrum tyrosine kinase inhibitor, has been approved for the treatment of advanced gastrointestinal stromal tumors in adult patients.
Jiahui Lin, Jiahui Lin, Aiting Jiang, Juntao Zheng, Jingjing Wu, Hao Li, Hao Li, Shirong Cai, Yulong He, Xiao Chen, Guoping Zhong, Ke-Jing Tang, Ke-Jing Tang, Xinhua Zhang, Yanzhe Xia   +14 more
doaj   +2 more sources

Ripretinib for the treatment of advanced gastrointestinal stromal tumor

Therapeutic Advances in Gastroenterology, 2021
Gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal (GI) tract yet represent the most common GI sarcomas. Most GISTs are driven by activating mutations of the KIT and/or PDGFRA genes.
John Zalcberg
exaly   +2 more sources

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications [PDF]

Future Science OA
Background Treatments for metastatic, unresectable, or treatment-resistant gastrointestinal stromal tumors (GIST) include avapritinib, imatinib, regorafenib, ripretinib, and sunitinib.
Cameron M. Thompson, Michael B. Andrews, Douglas G. Adler   +2 more
doaj   +2 more sources

Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with ripretinib: A single-center experience

Clinical Surgical Oncology, 2023
Background: Cytoreductive surgery (CRS) has been advocated as an additional treatment with survival benefits for advanced gastrointestinal stromal tumor (GIST), especially in patients with responsive disease or focal progression after treatment with ...
Yulong He, Kaiyu Sun, Zhaoming Guan
exaly   +3 more sources

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system [PDF]

Frontiers in Oncology
BackgroundRipretinib has been approved for the treatment of gastrointestinal stromal tumors (GIST). As a novel therapy, several adverse reactions remain unidentified, necessitating a thorough safety evaluation.
Sentai Wang, Hewen Chen, Yuying Zhou, Jianfeng Chen, Jiwei Cao   +4 more
doaj   +2 more sources